WntResearch AB (WNT.ST)
- Previous Close
0.1235 - Open
0.1235 - Bid 0.1170 x --
- Ask 0.1195 x --
- Day's Range
0.1155 - 0.1295 - 52 Week Range
0.0528 - 0.3790 - Volume
599,915 - Avg. Volume
2,185,209 - Market Cap (intraday)
103.494M - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. The company was incorporated in 2007 and is based in Lund, Sweden.
www.wntresearch.comRelated News
Performance Overview: WNT.ST
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WNT.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WNT.ST
Valuation Measures
Market Cap
106.96M
Enterprise Value
80.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.05%
Return on Equity (ttm)
-166.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-32.47M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
26.89M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-19M
Company Insights: WNT.ST
WNT.ST does not have Company Insights